On September 5, 2023 MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, reported that its partner, Gilead Sciences, Inc. (NASDAQ: GILD), nominated the first of two research programs, leveraging MacroGenics’ DART and TRIDENT platforms for generating bispecific antibodies (Press release, MacroGenics, SEP 5, 2023, View Source [SID1234634897]). This nomination grants Gilead an exclusive option, upon achievement of a pre-defined preclinical milestone, to license worldwide rights to the research program.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the October 2022 agreement, MacroGenics will receive $15 million related to the nomination of a bispecific research program to be conducted by MacroGenics and funded by Gilead. Pursuant to this agreement, which covers MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using MacroGenics’ DART platform, and up to two additional bispecific research programs, MacroGenics remains eligible to receive up to $1.7 billion in target nomination, option fees, and development, regulatory and commercial milestones. MacroGenics will also be eligible to receive tiered, double-digit royalties on worldwide net sales of MGD024 and a flat royalty on worldwide net sales of products under the two research programs.

On September 5, 2023 Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, reported that it will be presenting a poster at the 2023 European Association for Neuro-Oncology (EANO) Annual Meeting, taking place in Rotterdam, September 21-24, 2023 (Press release, Kintara Therapeutics, SEP 5, 2023, View Source [SID1234634896]). The presentation will include data from its lead program, VAL-083, for the treatment of recurrent glioblastoma.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the presentation are as follows:

Topic Section: Clinical neuro-oncology
Presentation Time: Saturday, September 23, 2023 – 5:15 p.m. to 6:45 p.m. CEST
Title: Phase 2 Study of VAL-083 and Radiotherapy in Newly Diagnosed MGMT-unmethylated GBM: Case Study Reports
Abstract/ Poster Number: P11.41.B
Presenter: Dr. Zong-ping Chen, Professor & Chairman of Department of Neurosurgery/Neuro-oncology of Sun Yat-sen University Cancer Center, Guangzhou, China & Dr. John Langlands, Kintara Therapeutics Inc, San Diego, CA
Abstracts will be published on the website of Neuro-Oncology on September 7, 2023.

Kintara recently hosted an event featuring key opinion leaders Patrick Y. Wen, M.D. (Harvard Medical School) and John de Groot, M.D. (UCSF Health) discussing the current treatment landscape for patients suffering from GBM along with Kintara’s potential treatment solution with VAL-083. More information about VAL-083 and its potential as a first-in-class small molecule chemotherapeutic for glioblastoma (GBM), can be found on the replay of that event here.

On September 5, 2023 Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, reported that the Company’s senior management team will participate in the following investor conferences in September (Press release, Karyopharm, SEP 5, 2023, View Source [SID1234634895]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 25th Annual Global Investment Conference
Format: Podium presentation
Date: Monday, September 11, 2023
Time: 12:30 p.m. ET

Morgan Stanley 21st Annual Global Healthcare Conference
Format: Fireside chat
Date: Tuesday, September 12, 2023
Time: 5:30 p.m. ET

Baird 2023 Global Healthcare Conference
Format: Fireside chat
Date: Wednesday, September 13, 2023
Time: 2:00 p.m. ET

A live webcast of the presentation and fireside chats, along with accompanying slides, can be accessed under "Events & Presentations" in the Investor section of the Company’s website, View Source, and will be available for replay for 90 days following each presentation.

On September 5, 2023 Intensity Therapeutics, Inc. (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, reported that Lewis H. Bender, President and Chief Executive Officer, will present a company overview at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, at 4:30 pm ET (Press release, Intensity Therapeutics, SEP 5, 2023, View Source [SID1234634893]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Bender will also host in-person and virtual one-on-one meetings during the event. Institutional investors who are registered for the conference can log into www.hcwevents.com to request a meeting with the company.

A live webcast of the presentation can be accessed here and will be available on the Intensity Therapeutics website at: View Source An archived replay will be available on the company’s website for approximately 90 days following the conclusion of the conference.

On September 5, 2023 IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company, announces that management will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 (Press release, IMUNON, SEP 5, 2023, https://investor.celsion.com/news-releases/news-release-details/imunon-participate-hc-wainwright-global-investment-conference [SID1234634892]). A webcast of the IMUNON presentation will be available on the Events section of the Company’s website beginning Monday, September 11 at 7:00 a.m. Eastern time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Management is available throughout the conference for virtual one-on-one meetings. Institutional investors and industry professionals can register to attend the conference virtually or in-person at the Lotte New York Palace Hotel.